Seasoned synthetic chemist, Dr. Damilola Akintayo, has called on the Nigerian government to prioritise research in antibiotic development to combat the growing threat of antibiotic resistance.

Speaking at a press briefing recently, he reiterated the urgent need for Nigeria to invest in science-led drug development to create tailored solutions for the country’s unique microbial challenges. “Antibiotic resistance is one of the biggest threats to public health in Nigeria and the world. From clinics in Lagos to hospitals in Kano, we are seeing common infections become harder to treat as bacteria evolve to resist the very drugs designed to kill them.”

Dr. Akintayo’s research focuses on the design and development of peptide-activated prodrugs, which remain inactive until they encounter specific enzymes produced by bacteria. This approach reduces off-target effects and minimizes the risk of resistance.

“The power of this approach lies in precision. By using peptides, short chains of amino acids, to guide and activate these drugs, we can selectively target resistant bacteria while leaving healthy cells unharmed,” he explained.

He further emphasised the need for Nigeria to shift from reactive treatment to smart, targeted intervention. “It is time to shift from reactive treatment to smart, targeted intervention. Imagine a future where antibiotics are activated only when and where they are needed,” he said.

He also highlighted the potential for Nigeria to become a global leader in antibiotic innovation.

Dr Akintayo’s experience in developing and improving peptide synthesis and designing small drug-like molecules to stop bacterial enzymes has equipped him with valuable insights into the potential of peptide-activated prodrugs. “During my time at the Peptide Research Laboratory at the University of KwaZulu-Natal, I focused on developing and improving the way peptides are made in the lab,” he shared.

Akintayo’s vision for the future of antibiotic development is built on the principles of precision and targeted intervention. “As scientists, we must bring the lab to life, not just in journals, but in policy, practice and public discourse,” he noted.

Dr. Akintayo’s work on structure-activity relationship (SAR) analysis has also provided valuable insights into the design of effective peptide-activated prodrugs.

Dr. Akintayo’s research experience at the Skaggs School of Pharmacy, University of Colorado Anschutz Medical Campus and the Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, has equipped him with a deep understanding of antibiotic resistance and the potential of peptide-activated prodrugs.

Akintayo is a renowned synthetic chemist with extensive experience in peptide synthesis and antibiotic development. His groundbreaking research offers a promising solution to the growing threat of antibiotic resistance and has the potential to revolutionise the field of medicine.